FUSION PHARMACEUTICALS INC's ticker is FUSN and the CUSIP is 36118A100. A total of 41 filers reported holding FUSION PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $27,777,851 | -44.2% | 10,683,789 | +0.5% | 0.07% | -40.3% |
| Q2 2023 | $49,766,133 | +125.7% | 10,633,789 | +81.8% | 0.12% | +125.5% |
| Q1 2023 | $22,051,107 | +117.1% | 5,849,100 | +81.4% | 0.06% | +96.4% |
| Q4 2022 | $10,155,915 | +6.3% | 3,224,100 | +1.6% | 0.03% | 0.0% |
| Q3 2022 | $9,555,000 | +22.8% | 3,174,100 | +1.6% | 0.03% | +33.3% |
| Q2 2022 | $7,779,000 | -67.2% | 3,124,100 | +2.3% | 0.02% | -61.1% |
| Q1 2022 | $23,738,000 | +261.6% | 3,055,037 | +94.1% | 0.05% | +350.0% |
| Q4 2021 | $6,564,000 | -43.0% | 1,574,000 | +8.3% | 0.01% | -45.5% |
| Q3 2021 | $11,514,000 | +138.4% | 1,453,890 | +143.2% | 0.02% | +144.4% |
| Q2 2021 | $4,830,000 | -20.3% | 597,841 | +5.8% | 0.01% | -25.0% |
| Q1 2021 | $6,057,000 | -1.8% | 565,000 | +7.6% | 0.01% | -7.7% |
| Q4 2020 | $6,169,000 | +0.6% | 525,000 | +2.9% | 0.01% | -7.1% |
| Q3 2020 | $6,130,000 | +9.7% | 510,000 | +59.4% | 0.01% | 0.0% |
| Q2 2020 | $5,590,000 | – | 320,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,670,516 | $11,562 | 3.36% |
| ADAMS STREET PARTNERS LLC | 2,947,809 | $9,285,598 | 3.10% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,560,984 | $4,917,100 | 2.14% |
| Sio Capital Management, LLC | 260,448 | $820,411 | 0.30% |
| BRAIDWELL LP | 2,000,000 | $6,300,000 | 0.21% |
| Orbimed Advisors | 3,224,770 | $10,158,026 | 0.19% |
| TPG GP A, LLC | 2,551,794 | $8,038,151 | 0.16% |
| Artal Group S.A. | 750,000 | $2,363 | 0.13% |
| RA Capital Management | 659,992 | $2,078,975 | 0.04% |
| SECTORAL ASSET MANAGEMENT INC | 57,297 | $180,486 | 0.04% |